BIOMAT Database Logo BIOMAT Database Logo

Multidrug- and extensively drug-resistant tuberculosis, Germany. 2008

Barbara Eker, and Johannes Ortmann, and Giovanni B Migliori, and Giovanni Sotgiu, and Ralf Muetterlein, and Rosella Centis, and Harald Hoffmann, and Detlef Kirsten, and Tom Schaberg, and Sabine Ruesch-Gerdes, and Christoph Lange, and
Research Center Borstel, Borstel, Germany.

We evaluated risk factors and treatment outcomes associated with multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) in Germany in 2004-2006. In 177 (4%) of 4,557 culture-positive TB cases, Mycobacterium tuberculosis isolates were identified as MDR TB; an additional 7 (0.15%) met criteria for XDR TB. Of these 184 patients, 148 (80%) were born in countries of the former Soviet Union. In patients with XDR TB, hospitalization was longer (mean +/- SD 202 +/- 130 vs. 123 +/- 81 days; p = 0.015) and resistance to all first-line drugs was more frequent (36% vs. 86%; p = 0.013) than in patients with MDR TB. Seventy-four (40%) of these 184 patients received treatment with linezolid. Treatment success rates ranged from 59% for the entire cohort (59% for MDR TB and 57% for XDR TB) to 87% for those with a definitive outcome (n = 125; 89% for MDR TB and 80% for XDR TB). Extensive drug susceptibility testing and availability of second- and third-line drugs under inpatient management conditions permit relatively high treatment success rates in MDR- and XDR TB.

UI MeSH Term Description Entries
D008297 Male Males
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D005260 Female Females
D005858 Germany A country in central Europe, bordering the Baltic Sea and the North Sea, between the Netherlands and Poland, south of Denmark. The capital is Berlin.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069349 Linezolid An oxazolidinone and acetamide derived ANTI-BACTERIAL AGENT and PROTEIN SYNTHESIS INHIBITOR that is used in the treatment of GRAM-POSITIVE BACTERIAL INFECTIONS of the skin and respiratory tract. Linezolide,N-((3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide,PNU-100766,U 100766,U-100766,Zyvox,100766, U,PNU 100766,PNU100766,U100766
D000081 Acetamides Derivatives of acetamide that are used as solvents, as mild irritants, and in organic synthesis.
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective

Related Publications

Barbara Eker, and Johannes Ortmann, and Giovanni B Migliori, and Giovanni Sotgiu, and Ralf Muetterlein, and Rosella Centis, and Harald Hoffmann, and Detlef Kirsten, and Tom Schaberg, and Sabine Ruesch-Gerdes, and Christoph Lange, and
Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis.
April 2015, Cold Spring Harbor perspectives in medicine,
Barbara Eker, and Johannes Ortmann, and Giovanni B Migliori, and Giovanni Sotgiu, and Ralf Muetterlein, and Rosella Centis, and Harald Hoffmann, and Detlef Kirsten, and Tom Schaberg, and Sabine Ruesch-Gerdes, and Christoph Lange, and
Multidrug-resistant and extensively drug-resistant tuberculosis.
March 2009, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease,
Barbara Eker, and Johannes Ortmann, and Giovanni B Migliori, and Giovanni Sotgiu, and Ralf Muetterlein, and Rosella Centis, and Harald Hoffmann, and Detlef Kirsten, and Tom Schaberg, and Sabine Ruesch-Gerdes, and Christoph Lange, and
Multidrug and extensively drug-resistant tuberculosis.
February 2017, Medecine et maladies infectieuses,
Barbara Eker, and Johannes Ortmann, and Giovanni B Migliori, and Giovanni Sotgiu, and Ralf Muetterlein, and Rosella Centis, and Harald Hoffmann, and Detlef Kirsten, and Tom Schaberg, and Sabine Ruesch-Gerdes, and Christoph Lange, and
Extensively drug-resistant tuberculosis, Italy and Germany.
May 2007, Emerging infectious diseases,
Barbara Eker, and Johannes Ortmann, and Giovanni B Migliori, and Giovanni Sotgiu, and Ralf Muetterlein, and Rosella Centis, and Harald Hoffmann, and Detlef Kirsten, and Tom Schaberg, and Sabine Ruesch-Gerdes, and Christoph Lange, and
Therapy of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.
March 2017, Microbiology spectrum,
Barbara Eker, and Johannes Ortmann, and Giovanni B Migliori, and Giovanni Sotgiu, and Ralf Muetterlein, and Rosella Centis, and Harald Hoffmann, and Detlef Kirsten, and Tom Schaberg, and Sabine Ruesch-Gerdes, and Christoph Lange, and
Multidrug-resistant and extensively drug-resistant tuberculosis: a review.
December 2008, Current opinion in infectious diseases,
Barbara Eker, and Johannes Ortmann, and Giovanni B Migliori, and Giovanni Sotgiu, and Ralf Muetterlein, and Rosella Centis, and Harald Hoffmann, and Detlef Kirsten, and Tom Schaberg, and Sabine Ruesch-Gerdes, and Christoph Lange, and
Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis.
September 2010, The Lancet. Infectious diseases,
Barbara Eker, and Johannes Ortmann, and Giovanni B Migliori, and Giovanni Sotgiu, and Ralf Muetterlein, and Rosella Centis, and Harald Hoffmann, and Detlef Kirsten, and Tom Schaberg, and Sabine Ruesch-Gerdes, and Christoph Lange, and
Multidrug-resistant and extensively drug resistant tuberculosis in Kashmir, India.
November 2009, Journal of infection in developing countries,
Barbara Eker, and Johannes Ortmann, and Giovanni B Migliori, and Giovanni Sotgiu, and Ralf Muetterlein, and Rosella Centis, and Harald Hoffmann, and Detlef Kirsten, and Tom Schaberg, and Sabine Ruesch-Gerdes, and Christoph Lange, and
Development of extensively drug-resistant tuberculosis during multidrug-resistant tuberculosis treatment.
August 2010, American journal of respiratory and critical care medicine,
Barbara Eker, and Johannes Ortmann, and Giovanni B Migliori, and Giovanni Sotgiu, and Ralf Muetterlein, and Rosella Centis, and Harald Hoffmann, and Detlef Kirsten, and Tom Schaberg, and Sabine Ruesch-Gerdes, and Christoph Lange, and
Multidrug- and extensively drug-resistant tuberculosis: an emerging threat.
December 2009, European respiratory review : an official journal of the European Respiratory Society,
Copied contents to your clipboard!